Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Multiplex Immunofluorescence of Bone Marrow Core Biopsies: Visualizing the Bone Marrow Immune Contexture.

Walters DK, Jelinek DF.

J Histochem Cytochem. 2019 Dec 19:22155419896802. doi: 10.1369/0022155419896802. [Epub ahead of print]

PMID:
31855110
2.

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M.

N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073.

PMID:
31365801
3.

Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia.

Tschumper RC, Shanafelt TD, Kay NE, Jelinek DF.

Oncotarget. 2019 Jan 1;10(1):60-75. doi: 10.18632/oncotarget.26538. eCollection 2019 Jan 1.

4.

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy.

Baliakas P, Mattsson M, Hadzidimitriou A, Minga E, Agathangelidis A, Sutton LA, Scarfo L, Davis Z, Yan XJ, Plevova K, Sandberg Y, Vojdeman FJ, Tzenou T, Chu CC, Veronese S, Mansouri L, Smedby KE, Giudicelli V, Nguyen-Khac F, Panagiotidis P, Juliusson G, Anagnostopoulos A, Lefranc MP, Trentin L, Catherwood M, Montillo M, Niemann CU, Langerak AW, Pospisilova S, Stavroyianni N, Chiorazzi N, Oscier D, Jelinek DF, Shanafelt T, Darzentas N, Belessi C, Davi F, Ghia P, Rosenquist R, Stamatopoulos K.

Haematologica. 2018 Apr;103(4):e158-e161. doi: 10.3324/haematol.2017.182634. Epub 2017 Dec 21. No abstract available.

5.

Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain.

Walters DK, Arendt BK, Tschumper RC, Wu X, Jelinek DF.

Exp Hematol. 2018 Jan;57:42-49.e1. doi: 10.1016/j.exphem.2017.09.010. Epub 2017 Oct 13.

6.

Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes.

Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt T, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfo L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan-Djurasevic T, Catherwood M, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin L, Montillo M, Niemann C, Döhner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K.

Clin Cancer Res. 2017 Sep 1;23(17):5292-5301. doi: 10.1158/1078-0432.CCR-16-3100. Epub 2017 May 23.

7.

CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.

Strati P, Parikh SA, Chaffee KG, Achenbach SJ, Slager SL, Call TG, Ding W, Jelinek DF, Hanson CA, Kay NE, Shanafelt TD.

Br J Haematol. 2017 Jul;178(1):99-105. doi: 10.1111/bjh.14647. Epub 2017 Apr 7.

8.

Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration.

Bergen HR 3rd, Dasari S, Dispenzieri A, Mills JR, Ramirez-Alvarado M, Tschumper RC, Jelinek DF, Barnidge DR, Murray DL.

Clin Chem. 2016 Jan;62(1):243-51. doi: 10.1373/clinchem.2015.242651. Epub 2015 Oct 1.

9.

Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.

Parikh SA, Leis JF, Chaffee KG, Call TG, Hanson CA, Ding W, Chanan-Khan AA, Bowen D, Conte M, Schwager S, Slager SL, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD.

Cancer. 2015 Sep 1;121(17):2883-91. doi: 10.1002/cncr.29438. Epub 2015 Apr 30.

10.

The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.

Boddicker RL, Kip NS, Xing X, Zeng Y, Yang ZZ, Lee JH, Almada LL, Elsawa SF, Knudson RA, Law ME, Ketterling RP, Cunningham JM, Wu Y, Maurer MJ, O'Byrne MM, Cerhan JR, Slager SL, Link BK, Porcher JC, Grote DM, Jelinek DF, Dogan A, Ansell SM, Fernandez-Zapico ME, Feldman AL.

Blood. 2015 May 14;125(20):3118-27. doi: 10.1182/blood-2014-05-578575. Epub 2015 Apr 1.

11.

Proteomic detection of immunoglobulin light chain variable region peptides from amyloidosis patient biopsies.

Dasari S, Theis JD, Vrana JA, Meureta OM, Quint PS, Muppa P, Zenka RM, Tschumper RC, Jelinek DF, Davila JI, Sarangi V, Kurtin PJ, Dogan A.

J Proteome Res. 2015 Apr 3;14(4):1957-67. doi: 10.1021/acs.jproteome.5b00015. Epub 2015 Mar 20.

PMID:
25734799
12.

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.

Lucas DM, Ruppert AS, Lozanski G, Dewald GW, Lozanski A, Claus R, Plass C, Flinn IW, Neuberg DS, Paietta EM, Bennett JM, Jelinek DF, Gribben JG, Hussein MA, Appelbaum FR, Larson RA, Moore DF Jr, Tallman MS, Byrd JC, Grever MR.

Leuk Lymphoma. 2015;56(11):3031-7. doi: 10.3109/10428194.2015.1023800. Epub 2015 Mar 30.

13.

Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.

Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton LA, Minga E, Tsanousa A, Scarfò L, Davis Z, Yan XJ, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, Tzenou T, Chatzouli M, Chu CC, Veronese S, Gardiner A, Mansouri L, Smedby KE, Pedersen LB, Moreno D, Van Lom K, Giudicelli V, Francova HS, Nguyen-Khac F, Panagiotidis P, Juliusson G, Angelis L, Anagnostopoulos A, Lefranc MP, Facco M, Trentin L, Catherwood M, Montillo M, Geisler CH, Langerak AW, Pospisilova S, Chiorazzi N, Oscier D, Jelinek DF, Darzentas N, Belessi C, Davi F, Ghia P, Rosenquist R, Stamatopoulos K.

Blood. 2015 Jan 29;125(5):856-9. doi: 10.1182/blood-2014-09-600874. Epub 2014 Dec 17.

14.

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

Correia C, Schneider PA, Dai H, Dogan A, Maurer MJ, Church AK, Novak AJ, Feldman AL, Wu X, Ding H, Meng XW, Cerhan JR, Slager SL, Macon WR, Habermann TM, Karp JE, Gore SD, Kay NE, Jelinek DF, Witzig TE, Nowakowski GS, Kaufmann SH.

Blood. 2015 Jan 22;125(4):658-67. doi: 10.1182/blood-2014-04-571786. Epub 2014 Dec 1.

15.

Immunoglobulin heavy variable (IGHV) genes and alleles: new entities, new names and implications for research and prognostication in chronic lymphocytic leukaemia.

Xochelli A, Agathangelidis A, Kavakiotis I, Minga E, Sutton LA, Baliakas P, Chouvarda I, Giudicelli V, Vlahavas I, Maglaveras N, Bonello L, Trentin L, Tedeschi A, Panagiotidis P, Geisler C, Langerak AW, Pospisilova S, Jelinek DF, Oscier D, Chiorazzi N, Darzentas N, Davi F, Ghia P, Rosenquist R, Hadzidimitriou A, Belessi C, Lefranc MP, Stamatopoulos K.

Immunogenetics. 2015 Jan;67(1):61-6. doi: 10.1007/s00251-014-0812-3. Epub 2014 Nov 12.

PMID:
25388851
16.

Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study.

Baliakas P, Hadzidimitriou A, Sutton LA, Minga E, Agathangelidis A, Nichelatti M, Tsanousa A, Scarfò L, Davis Z, Yan XJ, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, Tzenou T, Chatzouli M, Chu CC, Veronese S, Gardiner A, Mansouri L, Smedby KE, Pedersen LB, van Lom K, Giudicelli V, Francova HS, Nguyen-Khac F, Panagiotidis P, Juliusson G, Angelis L, Anagnostopoulos A, Lefranc MP, Facco M, Trentin L, Catherwood M, Montillo M, Geisler CH, Langerak AW, Pospisilova S, Chiorazzi N, Oscier D, Jelinek DF, Darzentas N, Belessi C, Davi F, Rosenquist R, Ghia P, Stamatopoulos K.

Lancet Haematol. 2014 Nov;1(2):e74-84. doi: 10.1016/S2352-3026(14)00005-2. Epub 2014 Nov 3.

PMID:
27030157
17.

Phenotyping polyclonal kappa and lambda light chain molecular mass distributions in patient serum using mass spectrometry.

Barnidge DR, Dasari S, Ramirez-Alvarado M, Fontan A, Willrich MA, Tschumper RC, Jelinek DF, Snyder MR, Dispenzieri A, Katzmann JA, Murray DL.

J Proteome Res. 2014 Nov 7;13(11):5198-205. doi: 10.1021/pr5005967. Epub 2014 Aug 26.

PMID:
25134970
18.

Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation.

Arendt BK, Walters DK, Wu X, Tschumper RC, Jelinek DF.

Oncotarget. 2014 Jul 30;5(14):5686-99.

19.

Eosinophil purification from human bone marrow.

Wong TW, Jelinek DF.

Methods Mol Biol. 2014;1178:21-7. doi: 10.1007/978-1-4939-1016-8_3.

PMID:
24986604
20.

TALEN-mediated genetic tailoring as a tool to analyze the function of acquired mutations in multiple myeloma cells.

Wu X, Blackburn PR, Tschumper RC, Ekker SC, Jelinek DF.

Blood Cancer J. 2014 May 9;4:e210. doi: 10.1038/bcj.2014.32.

21.

Eosinophils regulate peripheral B cell numbers in both mice and humans.

Wong TW, Doyle AD, Lee JJ, Jelinek DF.

J Immunol. 2014 Apr 15;192(8):3548-58. doi: 10.4049/jimmunol.1302241. Epub 2014 Mar 10.

22.

Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants.

Laurie CC, Laurie CA, Smoley SA, Carlson EE, Flinn I, Fridley BL, Greisman HA, Gribben JG, Jelinek DF, Nelson SC, Paietta E, Schaid D, Sun Z, Tallman MS, Weinshilboum R, Kay NE, Shanafelt TD.

Cancer Genet. 2014 Jan-Feb;207(1-2):19-30. doi: 10.1016/j.cancergen.2014.01.004. Epub 2014 Jan 17.

23.

Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS.

Barnidge DR, Tschumper RC, Theis JD, Snyder MR, Jelinek DF, Katzmann JA, Dispenzieri A, Murray DL.

J Proteome Res. 2014 Apr 4;13(4):1905-10. doi: 10.1021/pr5000544. Epub 2014 Mar 5.

PMID:
24552626
24.

A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union.

Grover RK, Zhu X, Nieusma T, Jones T, Boreo I, MacLeod AS, Mark A, Niessen S, Kim HJ, Kong L, Assad-Garcia N, Kwon K, Chesi M, Smider VV, Salomon DR, Jelinek DF, Kyle RA, Pyles RB, Glass JI, Ward AB, Wilson IA, Lerner RA.

Science. 2014 Feb 7;343(6171):656-661. doi: 10.1126/science.1246135.

25.

CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells.

Walters DK, Arendt BK, Jelinek DF.

Cell Cycle. 2013 Oct 1;12(19):3175-83. doi: 10.4161/cc.26193. Epub 2013 Sep 3.

26.

Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.

Greenberg AJ, Walters DK, Kumar SK, Rajkumar SV, Jelinek DF.

Eur J Haematol. 2013 Dec;91(6):504-13. doi: 10.1111/ejh.12192. Epub 2013 Sep 17.

27.

Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).

Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE, Zent CS.

Cancer. 2013 Nov 1;119(21):3788-96. doi: 10.1002/cncr.28292. Epub 2013 Aug 6. Erratum in: Cancer. 2014 Mar 15;120(6):926. Dosage error in article text.

28.

Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes.

Parikh SA, Rabe KG, Kay NE, Call TG, Ding W, Schwager SM, Bowen DA, Conte M, Jelinek DF, Slager SL, Shanafelt TD.

Haematologica. 2014 Jan;99(1):140-7. doi: 10.3324/haematol.2013.086066. Epub 2013 Aug 2.

29.

Induction of malignant plasma cell proliferation by eosinophils.

Wong TW, Kita H, Hanson CA, Walters DK, Arendt BK, Jelinek DF.

PLoS One. 2013 Jul 22;8(7):e70554. doi: 10.1371/journal.pone.0070554. Print 2013.

30.

Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells.

Wu X, Tschumper RC, Jelinek DF.

Leukemia. 2013 Nov;27(11):2264-7. doi: 10.1038/leu.2013.155. Epub 2013 May 20. No abstract available.

31.

Molecular analysis of immunoglobulin genes reveals frequent clonal relatedness in double monoclonal gammopathies.

Tschumper RC, Dispenzieri A, Abraham RS, Henderson KJ, Jelinek DF.

Blood Cancer J. 2013 Apr 19;3:e112. doi: 10.1038/bcj.2013.12.

32.

Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).

Shanafelt TD, Ramsay AG, Zent CS, Leis JF, Tun HW, Call TG, LaPlant B, Bowen D, Pettinger A, Jelinek DF, Hanson CA, Kay NE.

Blood. 2013 May 16;121(20):4137-41. doi: 10.1182/blood-2012-12-470005. Epub 2013 Mar 14.

PMID:
23493782
33.

Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach.

Baker A, Braggio E, Jacobus S, Jung S, Larson D, Therneau T, Dispenzieri A, Van Wier SA, Ahmann G, Levy J, Perkins L, Kim S, Henderson K, Vesole D, Rajkumar SV, Jelinek DF, Carpten J, Fonseca R.

Blood. 2013 Apr 18;121(16):3147-52. doi: 10.1182/blood-2012-07-443606. Epub 2013 Feb 19.

34.

The histone methyltransferase MMSET regulates class switch recombination.

Pei H, Wu X, Liu T, Yu K, Jelinek DF, Lou Z.

J Immunol. 2013 Jan 15;190(2):756-63. doi: 10.4049/jimmunol.1201811. Epub 2012 Dec 14.

35.

Purification of functional eosinophils from human bone marrow.

Wong TW, Jelinek DF.

J Immunol Methods. 2013 Jan 31;387(1-2):130-9. doi: 10.1016/j.jim.2012.10.006. Epub 2012 Oct 22.

36.

Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls.

Moreira J, Rabe KG, Cerhan JR, Kay NE, Wilson JW, Call TG, Leis JF, Jelinek DF, Schwager SM, Bowen DA, Hanson CA, Slager SL, Shanafelt TD.

Leukemia. 2013 Jan;27(1):136-41. doi: 10.1038/leu.2012.187. Epub 2012 Jul 11.

PMID:
22781591
37.

Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.

Shanafelt TD, Call TG, Zent CS, Leis JF, LaPlant B, Bowen DA, Roos M, Laumann K, Ghosh AK, Lesnick C, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE.

Cancer. 2013 Jan 15;119(2):363-70. doi: 10.1002/cncr.27719. Epub 2012 Jul 3.

38.

Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.

Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Bühler A, Oakes CC, Larson RA, Kay NE, Jelinek DF, Kipps TJ, Rassenti LZ, Gribben JG, Döhner H, Heerema NA, Marcucci G, Plass C, Byrd JC.

J Clin Oncol. 2012 Jul 10;30(20):2483-91. doi: 10.1200/JCO.2011.39.3090. Epub 2012 May 7.

39.

Comprehensive assessment of potential multiple myeloma immunoglobulin heavy chain V-D-J intraclonal variation using massively parallel pyrosequencing.

Tschumper RC, Asmann YW, Hossain A, Huddleston PM, Wu X, Dispenzieri A, Eckloff BW, Jelinek DF.

Oncotarget. 2012 Apr;3(4):502-13.

40.

Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation.

Arendt BK, Walters DK, Wu X, Tschumper RC, Huddleston PM, Henderson KJ, Dispenzieri A, Jelinek DF.

Leukemia. 2012 Oct;26(10):2286-96. doi: 10.1038/leu.2012.91. Epub 2012 Mar 30.

41.

Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse.

Braggio E, Kay NE, VanWier S, Tschumper RC, Smoley S, Eckel-Passow JE, Sassoon T, Barrett M, Van Dyke DL, Byrd JC, Jelinek DF, Shanafelt TD, Fonseca R.

Leukemia. 2012 Jul;26(7):1698-701. doi: 10.1038/leu.2012.14. Epub 2012 Jan 20. No abstract available.

42.

Differentiation of chronic lymphocytic leukemia B cells into immunoglobulin secreting cells decreases LEF-1 expression.

Gutierrez A Jr, Arendt BK, Tschumper RC, Kay NE, Zent CS, Jelinek DF.

PLoS One. 2011;6(10):e26056. doi: 10.1371/journal.pone.0026056. Epub 2011 Oct 6.

43.

Species D adenoviruses as oncolytics against B-cell cancers.

Chen CY, Senac JS, Weaver EA, May SM, Jelinek DF, Greipp P, Witzig T, Barry MA.

Clin Cancer Res. 2011 Nov 1;17(21):6712-22. doi: 10.1158/1078-0432.CCR-11-0968. Epub 2011 Sep 2.

44.

Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population.

Shanafelt TD, Kay NE, Rabe KG, Call TG, Zent CS, Schwager SM, Leis JF, Jelinek DF, Slager SL, Hanson CA.

Leukemia. 2012 Feb;26(2):373-6. doi: 10.1038/leu.2011.211. Epub 2011 Aug 12. No abstract available.

PMID:
21836611
45.

Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.

Mraz M, Zent CS, Church AK, Jelinek DF, Wu X, Pospisilova S, Ansell SM, Novak AJ, Kay NE, Witzig TE, Nowakowski GS.

Br J Haematol. 2011 Oct;155(1):53-64. doi: 10.1111/j.1365-2141.2011.08794.x. Epub 2011 Jul 12.

46.

Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX.

Walters DK, Wu X, Tschumper RC, Arendt BK, Huddleston PM, Henderson KJ, Dispenzieri A, Jelinek DF.

Leukemia. 2011 Aug;25(8):1344-53. doi: 10.1038/leu.2011.94. Epub 2011 May 13.

47.

Biological evaluation of CpG stimulation of normal human B-cells: implications for B-cell biology and cytogenetic analysis of CLL B-cells.

Wu X, Smoley SA, Peterson MA, Walters DK, Arendt BK, Nowakowski GS, Van Dyke DL, Kay NE, Jelinek DF.

Br J Haematol. 2011 May;153(3):402-5. doi: 10.1111/j.1365-2141.2010.08514.x. Epub 2011 Feb 17. No abstract available.

48.

Selective induction of DNA repair pathways in human B cells activated by CD4+ T cells.

Wu X, Tschumper RC, Gutierrez A Jr, Mihalcik SA, Nowakowski GS, Jelinek DF.

PLoS One. 2010 Dec 16;5(12):e15549. doi: 10.1371/journal.pone.0015549.

49.

Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy.

Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL, Jelinek DF, Tschumper RC, Kipps T, Byrd JC, Fonseca R.

Cancer Genet Cytogenet. 2010 Dec;203(2):161-8. doi: 10.1016/j.cancergencyto.2010.09.003.

50.

Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies.

Mihalcik SA, Tschumper RC, Jelinek DF.

Cell Cycle. 2010 Dec 15;9(24):4884-92. Epub 2010 Dec 15.

Supplemental Content

Loading ...
Support Center